The prospect who loved the demo probably isn’t going to buy. I know how that sounds. Go back through your last handful of closed deals, then the ones that stalled. The pattern is usually right there. The people who lit up, who said this is exactly what we’ve been looking for, went quiet a week later. The ones who signed were a little tense the whole way through. Most founders spend the quarter chasing the wrong half of that.
A founder I worked with runs a SaaS company. He’d built software that pulled a company’s scattered numbers into a single clean dashboard, so leadership could finally see the whole business at a glance. The demos were great. Managers leaned in, said their team would love it, said they’d wanted this kind of visibility for years. Then the same deals went quiet, one after another, and died.
He figured it was the messaging. He tightened the deck and rewrote the homepage. The number didn’t move. The problem was never the pitch. It was that the prospects who were most into it were the least likely to buy, which is a hard thing to believe about your own pipeline until you’ve watched it happen a dozen times.
The ones who signed weren’t excited. They were worried. One had missed his number the quarter before and knew he couldn’t do it again. Another had a board meeting coming and a forecast he couldn’t stand behind, with his name on it. None of them raved about the software. They asked pointed questions and moved fast.
Someone who’s enthusiastic is admiring what you built. Admiration is free. That’s a nice thing to get, and it costs them nothing, which is why you hear so much of it. A manager can sit in your demo, believe every word about how much better his team would run, and still never buy. Better someday doesn’t come with a date on it. That’s the problem with a pipeline full of agreement. It looks like momentum right up until the quarter ends and nothing has moved.
The people who actually buy have something the admirers don’t. A real problem, with a deadline, and their name on it. That VP wasn’t buying a cleaner dashboard. He was trying not to walk into his board with no answer. The clean reasons, more revenue, lower cost, less risk, are the ones that go in the business case, and they’re real. But that’s not what makes someone buy this quarter instead of next year. What makes them buy is that the problem is now theirs to solve, and everyone knows it.
So whether someone likes your product barely tells you if they’ll buy. Plenty of people like it. Some of them even buy. But the ones you can count on are already on the hook for the problem it solves.
There’s a frame for this you’ve almost certainly run into, and I’ll say up front it’s old. Vitamin or painkiller. A vitamin is good for you and easy to skip. Nothing falls apart the day you don’t take it. Tylenol is what you reach for when your head is already pounding, and you’re not standing in the aisle wondering whether pain relief is a smart long-term investment. You just want it gone.
On its own the metaphor doesn’t do much, which is probably why it gets repeated so often and used so badly. It comes out of product strategy, where the point is to help you decide what to build, and the advice is build the painkiller. Useful, if you’re at the whiteboard. You’re not. Your product already exists, and you’re not going to rebuild it every quarter to chase a mood. What you can change is who you put it in front of, and when. That’s the part founders skip. They take the metaphor, stamp the product a must-have or a nice-to-have, and move on, when the product was never the thing to label. The software my client built was a vitamin to the manager who admired it and Tylenol to the VP with the forecast he couldn’t defend. Same afternoon, same features, nothing about it changed. The only difference was what had happened to the two of them.
[Figure goes here: same product at top, two buyers below. Left, the admirer (vitamin, buys someday). Right, on the hook (Tylenol, buys now). Between them, the event, which happens on the buyer’s side. Rebuild in the Zenful brand palette. Alt text: “One product, two buyers. An event on the buyer’s side flips the admirer, for whom the product is a vitamin, into the on-the-hook buyer, for whom it is Tylenol.”]
Which is why a buyer doesn’t stay in one column. Something happens and moves him, usually somewhere you can’t see it. A board meeting gets scheduled. A number gets missed. The account that waved you off in March is suddenly, in September, the one calling you back, and your product sat there unchanged the whole time. The urgency was never in the product. It showed up in the buyer’s life. You can’t manufacture it, though that doesn’t stop anyone from trying.
I saw the same thing with another founder, this one selling compliance software. The kind that tracks your security controls and pulls together the evidence you need to pass a SOC 2 or ISO audit without losing a month to it. His message was make compliance easier. All true. Every buyer nodded along, agreed compliance mattered, and did nothing.
For a while he treated it as a wording problem. It wasn’t. There’s a wide gap between a buyer who thinks something matters and one who’s actually hurting. His were all in the first camp, nodding at a risk they figured they’d get to eventually. So he did what founders do when agreement won’t turn into money. He leaned on fear. Breach numbers. It’s not if, it’s when. The same siren every other security vendor was already blaring.
It cost him at both ends. The calm buyers could tell the urgency was staged, and it made them trust him less. The ones who were genuinely in trouble couldn’t hear him over the noise. Fear aimed at people who aren’t scared just annoys them, and it buries you under everyone else making the same racket.
When he finally looked hard at the customers he did have, none had bought out of fear of hackers. One had just lost a six-figure deal because procurement wanted security documentation he couldn’t produce. Another had a stack of security questionnaires sitting on his sales team’s desk, holding up deals that were ready to sign. For those two it was never about security. It was revenue stuck behind a review, with a number on it and a clock running, and someone upstairs waiting for an explanation. So the line changed. Not make compliance easier. Stop security reviews from blocking your enterprise deals. Same software. He stopped courting the people who agreed with him and started talking to the ones who were already bleeding.
This is where the vitamin question stops being about the words on your website. The two temperatures don’t just want different messages. They want close to two different companies.
If you’re selling to people who don’t feel the problem yet, the job is to create demand, and that’s slow by nature. You teach the cost of waiting. You build trust over months. You make sure you’re the name they already know on the day their situation finally turns, because it will turn, and you can’t put it on a calendar. Selling to someone who’s already in pain is a different job. They’re looking right now. The whole thing has to catch them in that window, say the consequence out loud, and get out of the way. Running one motion for both is how a lot of founder-led companies quietly stall.
Most founders are running a blend of the two without realizing it. Broad, educational content going out to everyone, and hard, urgent outbound going out to that same everyone, with a forecast propped up by people who reacted warmly and were never going to sign. The enthusiastic ones pile up in the pipeline. The genuinely stuck ones land in the same sequence as everyone else. And the founder decides the product must be broken. It usually isn’t. The motion just treats every buyer as if they’re in the same amount of pain, and they never are.
None of this makes the calm buyer a bad buyer, and it’s worth saying, because the trendy move is to write those people off. Some of the best customers you’ll land buy before the fire starts, on purpose, because they’d rather build the thing while there’s still time. They’re a different sale. One that rewards patience and punishes pressure. Push a vitamin buyer with book-a-demo-this-week energy and you’ve told him you make problems up. He can feel it, and he files it away.
When everyone likes it and nobody signs, the instinct is to add. More outbound, more features, another rep, a slicker deck. But piling volume onto a motion aimed at the wrong buyer just buys you more warm, going-nowhere interest, and it costs more than last quarter’s version did. Nothing was missing, so adding was never going to fix it. Your real market is smaller and more specific than the whole room of people who agree with you, and worth a lot more than the size of that room makes it look. The point was never to sell harder to everyone in it. It’s to find the few who are already hurting and build around them.
So go back and look at your most enthusiastic prospect, the one who loved all of it and still hasn’t signed. He might buy someday. Someday isn’t a stage in your pipeline. If you’re getting plenty of interest and no movement, it’s probably not the product, and it’s rarely the pitch. Somewhere in your motion, admiration and need are getting treated as the same thing, and they aren’t. Sort that out before you rewrite another deck or hire another rep. A Free Sales Consultation is a diagnostic conversation, not a pitch.
Book a Free Sales Consultation: https://calendly.com/laneylui/gtm-blueprint
